CRSF 7th Masterclass | First-Line Therapy for NTRK+ Lung Cancer by Dr. Bhavesh Poladia

Welcome to Day 3 of the 7th Masterclass in Lung Cancer by the Cancer Research and Statistic Foundation (CRSF). In this vital session, Dr. Bhavesh Poladia will provide insights into the Selection of First-Line Therapy for NTRK-Positive Lung Cancer. On July 21, 2024, at The Learning Galaxy, Urmi Estate, Lower Parel, Mumbai, Dr. Poladia will discuss the latest approaches and strategies for managing NTRK-positive non-small cell lung cancer (NSCLC). This presentation will focus on the current first-line treatment options available for patients with NTRK gene fusions, including the use of targeted therapies like TRK inhibitors. Dr. Poladia will cover clinical trial results, treatment guidelines, and practical considerations for selecting the most effective therapy based on individual patient profiles and tumor characteristics. The session will be valuable for oncologists, researchers, and healthcare providers seeking to optimize treatment strategies for NTRK-positive lung cancer. Supported by the Institute of Pulmonology Medical Research & Development (IPMRD) and SUNACT, with the Sunrise Oncology Centre as our Hospital Partner, this discussion will enhance your understanding of cutting-edge therapies in lung cancer treatment. #LungCancer #NTRKPositive #TargetedTherapy #CRSF #CancerResearch #OncologyMasterclass #DrBhaveshPoladia #NSCLC #CancerTreatment #PrecisionMedicine #SunriseOncologyCentre #IPMRD #Oncology